头部医美机构春节消费情况交流 20260223 摘要 2026 年初线下医美终端机构营收呈现波动，1 月同比增长 11%，2 月 受春节影响同比下降 4%，前两月整体增长约 6%，客流量上升 10%， 但客单价持续下降。 轻医美占比提升导致单价下降，机构需引进高利润产品或设备以保持利 润空间。监管趋严促进合规，支持新产品审批，增值税增加压力但可通 过合理抵扣缓解。 非手术项目占比持续提升至 66%-70%，光电皮肤类项目占比稳定在 40%-45%，注射类项目不断增加。光电皮肤设备市场在紧致抗衰方面 需求较高，但客单价可能持续下降。 注射类产品线将显著增长，玻尿酸、新型肉毒素、重组胶原蛋白等不断 推出新产品。机构积极布局 OEM 代工贴牌定制，以降低成本并提高利 润率。 玻尿酸市场中，进口高端品牌仍受欢迎，但 OEM 定制贴牌玻尿酸逐渐 成为主推项目，增速显著。传统品牌增速放缓，差异化新品牌表现出色。 重组胶原蛋白市场增速显著，预计 2026 年保持强劲增长。锦波公司占 据重要地位，但新进入者将形成冲击，新产品上市将扩大市场份额。 肉毒素产品线稳定增长，新款肉毒素获批上市有望继续推动销量增长。 童颜针市场竞争稳 ...

Group 1 - The core viewpoint of the news is that Lepu Medical (300003) is expected to see a significant increase in net profit in 2025, driven by a recovery in traditional business and breakthroughs in the medical aesthetics sector [1][2] - The company forecasts a net profit of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95%, ending a previous trend of decline [1] - The medical aesthetics business, particularly the Tongyan needle product, has rapidly gained traction since its launch in August 2025, generating approximately 100 million yuan in revenue by October 2025 [1] Group 2 - The financial report indicates that the growth in net profit is primarily due to the stabilization of traditional business and contributions from emerging sectors, with core cardiovascular intervention revenue showing steady growth [2] - The retail channel inventory for the pharmaceutical segment has been cleared, leading to double-digit growth in formulation revenue, while innovative drugs and medical aesthetics have become new sources of revenue [2] - The company expects a nearly 95% increase in net cash flow from operating activities, with a stable debt-to-asset ratio of 31%, indicating a solid financial position [2] Group 3 - Recently, Lepu Medical's stock price has shown limited volatility, closing at 17.98 yuan on February 11, 2026, with a slight decline of 0.17% on that day [3] - Over a 5-day period, the stock has seen a minor increase of 0.11%, but a notable decline of 11.38% over 20 days indicates short-term fluctuations [3] - The stock is positioned near the lower band of the Bollinger Bands, with weak MACD indicators, although the 60-day moving average provides support [3]

Group 1: Company Ratings and Collaborations - Haitong International maintains a "Buy" rating for Innovent Biologics (01801.HK), highlighting a new global strategic collaboration with Eli Lilly, which includes a $350 million upfront payment and up to $8.5 billion in milestone payments, focusing on innovative drug development in oncology and immunology [1] - CITIC Securities also maintains a "Buy" rating for Innovent Biologics, emphasizing the trust from multinational corporations in its innovative capabilities and projecting a 45% increase in product revenue by 2025, alongside the commercialization of 17 drugs and advancements in multiple Phase III pipelines [2] - Yuanta Securities maintains a "Buy" rating for Innovent Biologics, noting the new "China PoC + global development" model that enhances its R&D capabilities and forecasts product revenue to reach 11.9 billion yuan in 2025, a 45% year-on-year increase [3] Group 2: Other Company Ratings - CICC maintains an "Outperform" rating for Guoquan (02517.HK) with a target price of 4.90 HKD, citing steady same-store growth in the second half of 2025 and an accelerated store opening pace in 2026, with over half of its market share in rural areas [4] - CICC also maintains an "Outperform" rating for Kelun-Biotech (06990.HK) with a target price of 550 HKD, highlighting the approval of TROP2 ADC for new indications and significant commercial potential expected in 2026 [5] - Guohai Securities maintains a "Buy" rating for Sihuan Pharmaceutical (00460.HK), forecasting a return to profitability in the first half of 2025, with a significant revenue increase in its medical aesthetics segment [6] - Everbright Securities initiates coverage on Yujian Xiaomian (02408.HK) with an "Accumulate" rating and a target price of 4.90 HKD, noting its leading position in the Sichuan-Chongqing flavor noodle market and strong growth potential through market penetration [7] - Guoxin Securities initiates coverage on Power Development (01277.HK) with an "Outperform" rating, highlighting its leading profitability in the mining sector and upcoming production increases from key coal mines [8] - Guoxin Securities maintains an "Outperform" rating for China Oriental Education (00667.HK), noting a recovery in professional enrollment and an increase in net profit margin to 19.0% [9] - Guotou Securities maintains an "Accumulate" rating for Yum China (09987.HK), projecting a 3% same-store sales growth in Q4 2025 and plans for significant shareholder returns starting in 2027 [10]

二，炉边漫谈 毫无疑问，上周五美国财政部长对于美联储降息缩表的一番解释，大大缓解了市场的焦虑，而这也是今天全球股市暴涨的原因所在，那么这段话究竟是什么 意思呢？ 先说说「美联储的定心丸」：别慌，不会急着缩表 一，今日要点 今天沪指上演红周一，蛇年股市还有最后四个交易日，是否就此开启春节红包行情呢？ 最近市场不是揪着美联储换主席的事儿焦虑嘛？担心沃什上台后会不会「政策急转弯」、急着缩表抽流动性。结果美国财长贝森特出来「灭火」了：就算沃 什当主席（这家伙之前还批评过美联储买债券呢），也不会马上动手缩表；而且沃什会很独立，美联储可能得花一整年才会决定资产负债表的事儿。 其实市场怕的就是「突然收紧」——毕竟缩表意味着流动性变少，资金成本会涨。贝森特这话本质是安抚情绪，但说到底，美联储真要怎么做，还是得看资 金怎么解读：要是资金觉得「缩表节奏慢」，就敢放心进场；要是觉得「口说无凭」，照样会用脚投票。 再聊聊「特斯拉的光伏野心」：中国产业链要吃肉了 特斯拉又搞大动作——要扩大太阳能电池制造，三年目标冲100吉瓦！更关键的是：全球光伏产业链中国占绝对优势，马斯克就算想搞「太空光伏」（航 天、太空算力的能源核心），也绕不开中 ...

Core Viewpoint - New Oxygen is regaining pricing power in the medical beauty industry, which may lead to improved profitability despite previous challenges [4][5][8]. Group 1: Industry Dynamics - The medical beauty industry has seen a significant price war, with New Oxygen introducing competitively priced products like the "Miracle Youth 1.0" at 4,999 yuan, compared to the market price of 18,800 yuan for similar products [12][13]. - The industry is characterized by a fragmented pricing structure, where the same product can have vastly different prices across various platforms and institutions, indicating a loss of control by upstream manufacturers [15][16]. - New Oxygen's strategy includes a focus on "transparent medical beauty," aiming to make treatments affordable for a broader audience, including those with lower incomes [18][24]. Group 2: Cost Structure and Profitability - The cost structure of medical beauty products reveals that marketing costs can account for 30% to over 50% of expenses, while supply chain costs range from 20% to 30% [24][27]. - New Oxygen has managed to reduce its marketing costs to below 10% by leveraging community engagement and avoiding traditional sales models [28]. - Despite efforts to optimize costs, the overall profit margins in the industry remain low, with many downstream institutions operating at a loss [38][44]. Group 3: Company Performance and Strategy - New Oxygen has expanded its offline business with the launch of "New Oxygen Youth Clinics," aiming to increase its market presence and improve procurement power through large-scale purchases [41][49]. - The company has faced declining net profits, with figures showing a loss of 5.87 million yuan in 2025, highlighting the challenges in transitioning from an online to an offline model [44][48]. - The introduction of the "Miracle Youth" series has positively impacted New Oxygen's stock price, which rose significantly after the launch of the second version [50]. Group 4: Market Outlook - The market for micro-sphere regeneration products, including those offered by New Oxygen, is projected to reach 10.77 billion yuan by 2028, indicating substantial growth potential in this segment [51]. - The increasing approval of medical device registrations is expected to further dilute the pricing power of manufacturers, impacting overall industry profitability [33][37].

Core Viewpoint - The era of upstream medical beauty supply chain manufacturers relying solely on price control to maintain high profits may be coming to an end, indicating a significant shift in the industry's development logic [2][4]. Group 1: Industry Dynamics - New Oxygen has reached cooperation agreements with 14 upstream manufacturers, including major players like Allergan and Huaxi Biological, marking a pause in the pricing power battle that dominated the previous year [3]. - The medical beauty industry is experiencing a restructuring of power dynamics between upstream and downstream players, suggesting a transformation in the overall industry landscape [4]. Group 2: Pricing Strategies - New Oxygen's founder, Jin Xing, aims to lower the prices of medical beauty projects, citing high operational costs and supplier pricing as key factors for the inflated prices in China compared to countries like South Korea [6]. - The introduction of the "Miracle Tongyan 1.0" project by New Oxygen, priced at 4,999 yuan per unit, significantly undercuts the traditional market price of over 10,000 yuan, leading to backlash from suppliers [6][7]. - The pricing strategy continued to evolve with the launch of "Miracle Tongyan 3.0," which further reduced the price to 2,999 yuan, setting a new low in the industry [7]. Group 3: Supplier Relationships - Despite previous conflicts, some suppliers have reconciled with New Oxygen, indicating a shift in relationships as the market dynamics change [9]. - New Oxygen's purchasing power has increased, allowing it to negotiate better prices with suppliers, as it has established a significant presence with 50 stores across 16 cities by the end of 2025 [11]. Group 4: Market Supply and Demand - The balance of pricing power is shifting towards buyers, with an increase in the number of suppliers and products available, leading to a more competitive market environment [11][14]. - The regulatory environment is improving, with a significant increase in the number of medical beauty device registrations, which is expected to further enhance supply [13]. Group 5: Future Outlook - The medical beauty industry is transitioning from a phase of rapid, unregulated growth to a more structured and value-focused era, emphasizing the importance of quality over price competition [14][16]. - New Oxygen faces challenges in maintaining its scale while achieving profitability and balancing relationships with suppliers, which will be crucial for its successful transformation [15].

Core Viewpoint - The Chinese medical beauty industry is transitioning from chaotic growth to a more regulated, rational, and value-focused era [1][11] Group 1: Industry Dynamics - The era of upstream medical beauty suppliers relying solely on price control to maintain high profits is likely over, as evidenced by recent collaborations between New Oxygen and 14 upstream manufacturers [2] - The pricing power dynamics within the industry are shifting, with New Oxygen gaining leverage to negotiate prices due to its expanding network of stores [7] - The rapid development of the medical beauty industry has led to improved policy approval efficiency, resulting in a significant increase in the number of approved products [9] Group 2: Pricing Strategies - New Oxygen's founder, Jin Xing, aims to lower the prices of medical beauty projects, challenging the traditional high-price system that has persisted in the industry [3] - The introduction of New Oxygen's "Miracle Youth Needle" project at a price of 4,999 yuan per unit significantly undercuts the established market price, leading to backlash from suppliers [4] - The company has continued to innovate with pricing strategies, launching further iterations of its youth needle products at even lower prices, such as 2,999 yuan and 999 yuan [4] Group 3: Supplier Relationships - Despite previous conflicts, some brands that had publicly opposed New Oxygen have recently reconciled and entered into partnerships, indicating a shift in industry relationships [5] - New Oxygen's purchasing volume has reached significant levels, with some suppliers relying on the company for a substantial portion of their sales, fostering stable partnerships [9] Group 4: Future Outlook - The medical beauty industry is moving towards a model that emphasizes value over price competition, as the previous pricing wars have disrupted the long-standing pricing power of upstream manufacturers [10] - New Oxygen plans to expand its store presence significantly in key cities, aiming for a total of at least 35 new stores in 2026 [8] - The company remains optimistic about the future, believing that increased supply and improved technology will lead to more affordable services for consumers [8]

Core Viewpoint - The collaboration between medical beauty brands and "villains" signifies a shift in brand communication, aiming to inject confidence and vitality into the traditionally anxiety-ridden medical beauty marketing landscape [4][6]. Group 1: Industry Overview - The medical beauty industry in China has been characterized by a scarcity of quality and affordable services, leading to information asymmetry and regulatory gray areas that complicate consumer decision-making [9][10]. - Traditional medical beauty institutions often struggle with scalability, as many have been operating for over twenty years with limited store counts, typically between 20 to 40 [6][10]. - The industry is transitioning from a seller's market to a buyer's market due to an increase in product approvals, which is expected to enhance competition and reduce product scarcity [11][12]. Group 2: Company Development - New Oxygen has opened 50 direct-operated clinics across 16 cities and completed over 1 million treatments, positioning itself as a leader in the light medical beauty chain brand sector in China [5][4]. - The company has established the "Youth Selection Alliance," which sets stringent standards for product quality and aims to redefine what constitutes a "good product" in the market [15][16]. - New Oxygen's approach includes a focus on building a scalable and high-quality delivery system to address the industry's challenges of trust and efficiency [7][12]. Group 3: Supply Chain and Market Dynamics - The "Youth Selection Alliance" allows New Oxygen to leverage its treatment volume to negotiate better terms with suppliers, ensuring high-quality products are available to consumers [16][18]. - The company has formed partnerships with major pharmaceutical and medical beauty suppliers, significantly increasing its purchasing power and market influence [17][18]. - New Oxygen's strategy emphasizes the importance of a robust supply chain and efficient distribution channels, which are critical for driving down costs and enhancing product availability [20][21]. Group 4: Future Outlook - The transformation within the medical beauty industry is expected to lead to a healthier ecosystem and a more rational consumer market, characterized by increased choice, transparency, and trust [27][28]. - As the industry moves towards full market competition, companies that can effectively balance consumer trust and supply chain efficiency will thrive [27][28]. - New Oxygen's ongoing efforts to integrate technology and streamline operations are essential for overcoming existing industry challenges and achieving sustainable growth [22][28].

Core Insights - Company is accelerating its scale operations by collaborating with 14 upstream suppliers and plans to open 35 new offline stores in the coming year, transitioning from an online medical beauty platform to a physical medical institution with a low-price model [1][6][7] Group 1: Strategic Partnerships - The establishment of the "Youth Selection Alliance" with 14 upstream suppliers aims to achieve mutual growth through price linkage, tiered supply, training collaboration, and product traceability [3] - This partnership indicates an improvement in the pricing issues that previously strained relationships with suppliers, allowing for a more stable collaboration [3][5] - Notable suppliers in this alliance include Allergan, Medimime, and others, which have previously raised concerns over pricing discrepancies with the company [3][4] Group 2: Pricing Strategy - The company has consistently aimed to lower the prices of its products, such as the "童颜针" (youthful needle), which saw significant price reductions over the years, making it more accessible to consumers [4][6] - The low-price strategy is seen as a way to attract new consumers, although the long-term sustainability of this approach will depend on product effectiveness and perceived value [4][5] Group 3: Operational Expansion - As of now, the company has established 50 stores across 16 cities, with plans to add at least 35 more stores by the end of 2026, aiming for a total of 500 doctors and 1000 nursing staff [7] - The company is entering a strategic transformation phase, focusing on improving operational gross margins while maintaining its scale advantage [7][8] Group 4: Financial Performance - The company reported a total revenue of 1.063 billion yuan for the first three quarters of 2025, a decrease of 3.17% year-on-year, with a loss of 133 million yuan [8][9] - The beauty treatment services segment has become the largest revenue source, contributing 427 million yuan, a significant increase of 385.05% year-on-year, accounting for 40.16% of total revenue [9] - The goal for 2026 includes achieving quarterly profitability while enhancing gross margins through a diverse product offering [8][9]

Core Viewpoint - The medical beauty industry is experiencing a shift from supply scarcity to abundance, allowing institutions to negotiate better prices and providing more options for consumers [2][3][9]. Group 1: Market Dynamics - New Oxygen's "Miracle Youth" project has seen continuous sales growth for three months since its launch, despite pricing disputes with upstream suppliers [2]. - The price of "Miracle Youth" products is significantly lower than the manufacturer's suggested retail price, with some products priced at 60% less than the official price [2][5]. - The increase in the number of products available in the market has provided institutions with more choices, reducing reliance on single suppliers [3][9]. Group 2: Competitive Landscape - The market for "Miracle Youth" products, specifically the PLLA facial filler, has seen multiple companies approved for production, increasing competition [5]. - New Oxygen's pricing strategy has led to conflicts with suppliers, who are concerned about the disruption of established pricing structures [6]. - The number of approved products in the PLLA category is expected to grow, with 11 products already approved and nearly 20 more in the pipeline [9]. Group 3: Business Strategy - New Oxygen aims to leverage its scale by expanding its number of clinics and increasing treatment volumes, which enhances its negotiating power with suppliers [6][7]. - The company plans to open at least 35 new clinics by 2026, with a target of increasing the number of doctors and nursing staff significantly [7]. - Despite ongoing losses due to expansion, New Oxygen's strategy focuses on achieving profitability by optimizing operations and offering a wider range of products at different price points [11].